Your Article Summary
See Latest ArticlesPharmacogenetics and the potential for the individualization of antiretroviral therapy
Current Opinion in Infectious Diseases, 01/22/08
Phillips EJ et al. - Differences in HIV acquisition and progression as well as antiretroviral efficacy and toxicity will continue to provide the basis for research to define the genetic basis of such diversity. Despite the plethora of research in this area, numerous barriers exist to the successful operationalization of genetic testing to the clinic. HLA-B5701 screening to prevent abacavir hypersensitivity is currently the most relevant to clinical practice and highlights that the promise of cost-effective testing can be facilitated by robust laboratory methodology and quality assurance programs that can be applied to diverse treatment settings
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/07/09
Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults
Antimicrobial Agents and Chemotherapy, 12/07/09
Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B
International Journal of Infectious Diseases, 12/04/09